EC Microbiology

Review Article Volume 19 Issue 6 - 2023

CRISPR-Modified Neurofibromin Can Help Suppress the Leukemic PI3K Signalling Pathway

Akanksha Awadhesh Singh*

Department of Biotechnology, Rashtrasant Tukadoji Maharaj Nagpur University, India

*Corresponding Author:Akanksha Awadhesh Singh, Department of Biotechnology, Rashtrasant Tukadoji Maharaj Nagpur University, India.
Received: February 15, 2023; Published: May 20, 2023

Leukaemia is the type of the cancer that mainly deals with the formation of the haemo-tissues in the regions like lymphatic system and the bone marrow. Several pathways associated to the leukaemia have been found by the scientists over the globe. Interestingly, the most important and one of the critical pathways is the AKT/PI3K pathway that involves a plethora of the cytokines and the growth factors. This PI3K pathway plays a major in the biological processes like angiogenesis, apoptosis, proliferation of the cells and the signal transduction related events. But, have you ever been intrigued by the fact if this prime pathway can be regulated? If regulated, then what are those key control factors and how can we regulate it in case of blood cancer? Neurofibromin is a protein that is mainly encoded by the NF1 gene with 2818 amino acids with a molecular mass of around 250 - 280 kDa that is involved in the GAP related activities and known to negatively regulate the RAS signal transduction pathway and this pathway plays a major role in the PI3K pathway. So, there is an urgent needed to engineer the RAS protein in order the PI3K activity. Reportedly, the mice that were mutated with the PI3K protein did not form cancers. This review emphasizes on the dominant activity of the Neurofibromin protein engineered by the CRISPR technology that can indirectly regulate the PI3K pathway.

Keywords: Leukaemia; Haemo-Tissues; Lymphatic; Bone Marrow; Signal Transduction; Neurofibromin

  1. Bergoug M., et al. “Neurofibromin Structure, Functions and Regulation”. Cells11 (2020): 2365.
  2. Wallace MR., et al. “A chromosome jump crosses a translocation breakpoint in the von Recklinghausen neurofibromatosis region”. Genes, Chromosomes and Cancer4 (1990): 271-277.
  3. Sherekar M., et al. “Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer”. Journal of Biological Chemistry4 (2020): 1105-1119.
  4. Anastasaki C., et al. “RAS and beyond: the many faces of the neurofibromatosis type 1 protein”. Disease Models and Mechanisms2 (2022): dmm049362.
  5. Castellano E and Downward J. “RAS Interaction with PI3K: More Than Just Another Effector Pathway”. Genes Cancer3 (2011): 261-274.
  6. Johannessen CM., et al. “The NF1 tumor suppressor critically regulates TSC2 and mTOR”. Proceedings of the National Academy of Sciences24 (2005): 8573-8578.
  7. Yu J., et al. “Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit”. Molecular and Cellular Biology3 (1998): 1379-1387.
  8. Hiatt KK., et al. “Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1−/− cells”. Journal of Biological Chemistry10 (2001): 7240-7245.
  9. Dunzendorfer-Matt T., et al. “The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation”. Proceedings of the National Academy of Sciences of the United States of America27 (2016): 7497-7502.
  10. Katagiri H., et al. “Overexpression of catalytic subunit p110alpha of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3- L1 adipocytes”. Journal of Biological Chemistry29 (1996): 16987-16990.
  11. Visconti L., et al. “The kinetics of folding of the NSH2 domain from p85”. Scientific Reports 9 (2019): 4058.

Akanksha Awadhesh Singh. “CRISPR-Modified Neurofibromin Can Help Suppress the Leukemic PI3K Signalling Pathway”. EC Microbiology  19.6 (2023): 01-05.